Taylor & Francis Group
3 files

Intralesional corticosteroid administration in the treatment of keloids: a survey among Dutch dermatologists and plastic surgeons

Version 2 2023-01-18, 09:20
Version 1 2023-01-03, 13:20
posted on 2023-01-18, 09:20 authored by Qi Yin, Frank B. Niessen, Susan Gibbs, Oren Lapid, Juliette M. I. Louter, Paul P. M. van Zuijlen, Albert Wolkerstorfer

Intralesional corticosteroid administration (ICA) is a first-line therapy in keloid treatment. However, its clinical results are still highly variable and often suboptimal. Treatment results may strongly be influenced by various ways of ICA.

To explore the prevailing practice of ICA in keloid treatment among dermatologists and plastic surgeons in the Netherlands.

The survey was constructed based on a scoping review on ICA in keloid treatment. Members of the Dutch Society for Plastic surgery and the Dutch Society for Dermatology and Venereology were asked to participate.

One hundred and thirty-six responses were obtained. One hundred and thirty (95.6%) participants used triamcinolone acetonide. The majority (54.7%) did not use local anesthesia for pain reduction. Reported corticosteroid dosing that one would inject in one specific keloid differed by a factor of 40. Treatment intervals varied from 1 week to more than 8 weeks. The keloid center was most often injected (46.9%), followed by subepidermal (18.0%).

A wide variety in ICA for keloids is noted among dermatologists and plastic surgeons, even in a limited geographic region and when evidence points toward an optimal way of treatment. Future studies and better implementation of existing evidence may reduce variation in ICA and optimize its treatment results.


Usage metrics

    Journal of Dermatological Treatment



    Ref. manager